The potential of PSMA-targeted alpha therapy in the management of prostate cancer

References

• Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89.
   PubMedGoogle Scholar
• Karl A, Konety B. Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences. F1000 Med Rep. 2009. DOI:10.3410/M1-2
   PubMedGoogle Scholar
• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642.
   PubMed Web of Science ®Google Scholar
• Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
   PubMed Web of Science ®Google Scholar
• Elgqvist J, Frost S, Pouget JP, et al. The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol. 2014;3:324.
   PubMedGoogle Scholar
• Filippi L, Basile P, Schillaci O, et al. The relationship between total lesion activity on 18 F choline positron emission tomography-computed tomography and clinical outcome in patients with castration-resistant prostate cancer bone metastases treated with 223 radium. Cancer Biother Radiopharm. 2020;35:398–403.
   PubMed Web of Science ®Google Scholar
• Ceci F, Fanti S. PSMA-PET/CT imaging in prostate cancer: why and when. Clin Transl Imaging. 2019;7:377–379.
   Web of Science ®Google Scholar
• Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.
   PubMed Web of Science ®Google Scholar
• McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537–1540.
   PubMed Web of Science ®Google Scholar
• Asaithamby A, Chen DJ. Mechanism of cluster DNA damage repair in response to high-atomic number and energy particles radiation. Mutat Res. 2011;711:87–99.
   PubMed Web of Science ®Google Scholar
• Timm S, Lorat Y, Jakob B, et al. Clustered DNA damage concentrated in particle trajectories causes persistent large-scale rearrangements in chromatin architecture. Radiother Oncol. 2018;12:600–610.
   Web of Science ®Google Scholar
• Bannik K, Madas B, Jarzombek M, et al. Radiobiological effects of the alpha emitter Ra-223 on tumor cells. Sci Rep. 2019;9:18489.
   PubMed Web of Science ®Google Scholar
• Sgouros G, Knox SJ, Joiner MC, et al. MIRD continuing education: bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med. 2007;48:1683–1691.
   PubMed Web of Science ®Google Scholar
• Azzam EI, de Toledo SM, Little JB. Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha -particle irradiated to nonirradiated cells. Proc Natl Acad Sci USA. 2001;98:473–478.
   PubMed Web of Science ®Google Scholar
• Iyer R, Lehnert BE. Factors underlying the cell growth-related bystander responses to a particles. Cancer Res. 2000;60:1290–1298.
   PubMed Web of Science ®Google Scholar
• de Kruijff RM, Wolterbeek HT, Denkova AG. A critical review of alpha radionuclide therapy-how to deal with recoiling daughters? Pharmaceuticals (Basel). 2015;8(2):321–336.
   PubMedGoogle Scholar
• Filippi L, Scopinaro F, Pelle G, et al. Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2016;43:432–440.
   PubMed Web of Science ®Google Scholar
• Hope TA, Calais J, Zhang L, et al. 111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on krenning scores and effect of tumor burden. J Nucl Med. 2019;60:1266–1269.
   PubMed Web of Science ®Google Scholar
• Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6(S 10):S13–188.
   PubMedGoogle Scholar
• Chang SS, O’Keefe DS, Bacich DJ, et al. Identification of a novel tumor-associated neovasculature marker: prostate-specific membrane antigen (PSMA). Clin Cancer Res. 1999;5:2674–2681.
   PubMed Web of Science ®Google Scholar
• Kasperzyk JL, Finn SP, Flavin R, et al. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:2354–2363.
   PubMed Web of Science ®Google Scholar
• Taneja SS. ProstaScint(R) scan: contemporary use in clinical practice. Rev Urol. 2004;6(S10):S19–S28.
   PubMedGoogle Scholar
• Sonni I, Eiber M, Fendler WP, et al. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single center study. J Nucl Med. 2020. DOI:10.2967/jnumed.119.237602
   PubMed Web of Science ®Google Scholar
• Umbricht CA, Köster U, Bernhardt P, et al. Alpha-PET for prostate cancer: preclinical investigation using 149Tb-PSMA-617. Sci Rep. 2019;9:17800.
   PubMed Web of Science ®Google Scholar
• Morgenstern A, Apostolidis C, Kratochwil C, et al. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11:200–208.
   PubMed Web of Science ®Google Scholar
• Morgenstern A, Bruchertseifer F, Apostolidis C. Bismuth-213 and actinium-225 – generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes. Curr Radiopharm. 2012;5(3):221–227.
   PubMedGoogle Scholar
• Thiele NA, Wilson JJ. Actinium-225 for targeted a therapy: coordination chemistry and current chelation approaches. Cancer Biother Radiopharm. 2018;33:336–348.
   PubMed Web of Science ®Google Scholar
• Benešová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–920.
   PubMed Web of Science ®Google Scholar
• Ruegg CL, Anderson-Berg WT, Brechbiel MW, et al. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990;50:4221–4226.
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted a-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–1944.
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–1631.
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802.
   PubMed Web of Science ®Google Scholar
• Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61:62–69.
   PubMed Web of Science ®Google Scholar
• Khreish F, Ebert N, Ries M, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721–728.
   PubMed Web of Science ®Google Scholar
• McDevitt MR, Barendswaard E, Ma D, et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095–6100.
   PubMed Web of Science ®Google Scholar
• Li Y, Tian Z, Rizvi SM, et al. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis. 2002;5:36–46.
   PubMed Web of Science ®Google Scholar
• Sathekge M, Knoesen O, Meckel M, et al. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1099–1100.
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Schmidt K, Afshar-Oromieh A, et al. Targeted alpha therapy of mCRPC: dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45:31–37.
   PubMed Web of Science ®Google Scholar
• Frantellizzi V, Cosma L, Brunotti G, et al. Target Alpha Therapy with Thorium-227. Cancer Biother Radiopharm. 2020;35:437–445.
   PubMed Web of Science ®Google Scholar
• Hammer S, Hagemann UB, Zitzmann-Kolbe S, et al. Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer. Clin Cancer Res. 2020;26:1985–1996.
   PubMed Web of Science ®Google Scholar
• Current K, Meyer C, Magyar CE, et al. Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity. Clin Cancer Res. 2020;26:2946–2955.
   PubMed Web of Science ®Google Scholar
• Langbein T, Chaussé G, Baum RP. Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies. J Nucl Med. 2018;59:1172–1173.
   PubMed Web of Science ®Google Scholar
• Baum RP, Langbein T, Singh A, et al. Injection of botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: an empirical proof of a promising concept. Nucl Med Mol Imaging. 2018;52:80–81.
   PubMed Web of Science ®Google Scholar
• Sathekge M, Bruchertseifer F, Knoesen O, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–138.
   PubMed Web of Science ®Google Scholar